Credit Capital Investments LLC Makes New $260,000 Investment in Pfizer Inc. (NYSE:PFE)

Credit Capital Investments LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 9,800 shares of the biopharmaceutical company’s stock, valued at approximately $260,000. Pfizer accounts for 0.3% of Credit Capital Investments LLC’s holdings, making the stock its 27th biggest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. PSI Advisors LLC increased its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 385 shares in the last quarter. Waddell & Associates LLC raised its holdings in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 388 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its position in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. lifted its position in Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 391 shares in the last quarter. Finally, Lipe & Dalton lifted its position in Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.0 %

PFE opened at $26.31 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $149.09 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company’s 50-day moving average price is $26.21 and its two-hundred day moving average price is $27.09.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PFE. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.